| Contents per vial | 10 mg |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | 99,96 % (HPLC) |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | C51H84N16O21 |
| Molecular weight | 1257,31 g/mol |
| Sequence or structure | pGlu–Gln–Leu–Glu–Arg–Ala–Leu–Asn–Ser–Ser |
| CAS | 1208243-50-8 |
| Intended use | For laboratory research only |
About this product
ARA-290, also known as cibinetide, is an erythropoietin-derived peptide designed to maintain tissue protective signaling without stimulating red blood cell production. It is mainly investigated for neuropathic pain, nerve damage and inflammatory processes. Smaller clinical studies investigated, for example, small-fiber neuropathy. The results are interesting, but it is not an established treatment. The peptide is particularly important for innate repair receptor research.
What is ARA-290?
From a scientific perspective, ARA-290 represents a substance classified as a synthetic peptide or peptide analog. Its experimental profile is mainly assessed through neuropathic pain, small-fiber neuropathy, tissue protection, inflammation, while individual research questions can use different cell, tissue or organism models. Binding to target structures, subsequent signaling and changes in selected biological indicators are monitored.
Mechanism of action under investigation
ARA-290 targets the so-called innate repair receptor, a heterocomplex associated with the EPO receptor and CD131. It is supposed to activate protective signals without a classic erythropoietic response.
MAIN AREAS OF RESEARCH
• Neuropathic pain: ARA-290, also known as cibinetide, is being investigated for histoprotective signaling associated with nerve damage and neuropathic pain.
• Small-fiber neuropathy: Clinical research has evaluated both the symptoms and the density of small nerve fibers in the skin in small-fiber neuropathy.
• Protection of damaged tissue: The peptide was designed to activate the protective part of erythropoietin signaling without stimulating red blood cell production.
• Nerve tissue inflammation: Research is looking at limiting the inflammatory response and cell damage following nerve or tissue stress.
Research findings to date
Work to date on the substance ARA-290 is devoted to areas that include neuropathic pain, small-fiber neuropathy, tissue protection, inflammation. Results should be assessed according to the level of evidence: cell and animal models. Smaller clinical studies investigated, for example, small-fiber neuropathy. The peptide is particularly important for innate repair receptor research. With experimental peptides, the risk of a local reaction, immunogenicity or an unpredictable biological response must also be taken into account; these possibilities cannot be considered a complete clinical list.
